This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

High Expectations Still Haunt Intuitive Surgical

NEW YORK (TheStreet) -- I've become somewhat perplexed witnessing what has gone on with shares of Intuitive Surgical (ISRG - Get Report), which are down 8% following what was on balance a strong fourth-quarter performance.

In odd fashion, investors cheered when management preannounced its results, advising that revenue was going to be down 5% for the quarter. The stock shot up as much as 7% -- only to see the shares get punished mercilessly when management released the actual results just days later. This makes absolutely no sense. The surprise was gone. This reaction goes back to what I said three months ago about the level of irrationality that remain with this company.

In the November article, I said:

Given the tone of this article, investors will likely be upset and I understand that. But I've never been one to chase a growth story, especially when it seems too good to be true. But there's no one to blame for willfully ignoring the warning signs, many of which Intuitive have provided.

That said, I do believe these shares will rebound. It's just not going to happen right away. There are plenty of operational issues management must first address. Not the least of which has to do with the wellbeing of customers who use their products. As with St. Jude Medical (STJ), Intuitive is operating under a warning letter from the Food and Drug Administration. But unlike St. Jude, Intuitive shares are now feeling the pressure.

At the risk of sounding like I'm tooting my own horn, it looks as if I was spot on. Look, it's not Intuitive's fault that the Street has had a love affair with its stock. Known for its daVinci surgical robots, which has dominated areas like the prostatectomy market, this company has been one of the cleanest growth stories in med-tech space. There's no disputing that.

My problem has always been with those who claim that "valuation doesn't matter." The more growth this company provided, expectations went higher. To its credit, over the past couple of years, Intuitive has delivered the goods. The stock has been gainfully rewarded, climbing from $100 in 2009 to $583 last year. All of a sudden, valuation matters.

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
SYM TRADE IT LAST %CHG
ISRG $505.92 -1.34%
AAPL $130.28 0.47%
FB $81.53 -1.07%
GOOG $565.06 3.30%
TSLA $218.42 -0.08%

Markets

DOW 18,080.14 +21.45 0.12%
S&P 500 2,117.69 +4.76 0.23%
NASDAQ 5,092.0850 +36.0220 0.71%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs